Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [31] First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO
    Rexer, H.
    Retz, M.
    Hammerer, P.
    UROLOGE, 2021, 60 (07): : 987 - 988
  • [32] The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
    Armstrong, Andrew J.
    Iguchi, Taro
    Azad, Arun
    Villers, Arnauld
    Alekseev, Boris
    Petrylak, Daniel P.
    Szmulewitz, Russell Zelig
    Alcaraz, Antonio
    Shore, Neal D.
    Holzbeierlein, Jeffrey
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Haas, Gabriel P.
    Gourgioti, Georgia
    El-Chaar, Nader N.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [33] Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.
    Shore, Neal D.
    Armstrong, Andrew J.
    Szmulewitz, Russell Zelig
    Petrylak, Daniel Peter
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
    Sternberg, Cora N.
    Fizazi, Karim
    Saad, Fred
    Shore, Neal D.
    De Giorgi, Ugo
    Penson, David F.
    Ferreira, Ubirajara
    Ivashchenko, Petro
    Efstathiou, Eleni
    Madziarska, Katarzyna
    Kolinsky, Michael Paul
    Cubero, Daniel Iracema
    Noerby, Bettina
    Zohren, Fabian
    Lin, Xun
    Modelska, Katharina
    Sugg, Jennifer
    Steinberg, Joyce Leta
    Hussain, Maha H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Darolutamide plus androgen-deprivation therapy in patients with high-risk biochemical recurrence of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP)
    Chehrazi-Raffle, Alex
    Morgans, Alicia K.
    Gschwed, Jurgen E.
    Shore, Neal D.
    Ross, Ashley
    Feng, Felix Y.
    Hope, Thomas A.
    Nordquist, Luke
    Niazi, Tamim
    Trandafir, Lucia
    Le Berre, Marie-Aude
    Kuss, Iris
    Joensuu, Heikki
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)
    Carducci, M.
    Armstrong, A.
    Pili, R.
    Ng, S.
    Huddart, R.
    Agarwal, N.
    Khvorostenko, D.
    Lyulko, O.
    Brize, A.
    Vogelzang, N. J.
    Delva, R.
    Harza, M.
    Thanos, A.
    James, N.
    Werbrouck, P.
    Boegemann, M.
    Hutson, T.
    Milecki, P.
    Nederman, T.
    Sternberg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S713 - S714
  • [37] China ARCHES: A multicenter phase III randomized doubleblind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) vs PBO plus ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
    Zhou, F.
    Gongqian, Z.
    Guo, H.
    Hu, Z.
    Zhang, X.
    He, D.
    He, Z.
    Zhang, D.
    Li, Y.
    Kadeerbai, H.
    Liu, Y.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S971 - S971
  • [38] Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
    Sternberg, Cora
    Armstrong, Andrew
    Pili, Roberto
    Ng, Siobhan
    Huddart, Robert
    Agarwal, Neeraj
    Khvorostenko, Denis
    Lyulko, Olexiy
    Brize, Arija
    Vogelzang, Nicholas
    Delva, Remy
    Harza, Mihai
    Thanos, Anastasios
    James, Nicholas
    Werbrouck, Patrick
    Boegemann, Martin
    Hutson, Thomas
    Milecki, Piotr
    Chowdhury, Simon
    Gallardo, Enrique
    Schwartsmann, Gilberto
    Pouget, Jean-Christophe
    Baton, Frederique
    Nederman, Thore
    Tuvesson, Helen
    Carducci, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2636 - U136
  • [39] A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).
    Haresh, K. P.
    Vjaters, Egils
    Castellano, Daniel
    Olmos, David
    Shore, Neal D.
    Nevalaita, Liina
    Testa, Isabella
    Kappeler, Christian
    Kuss, Iris
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial
    Norz, Valentina
    Lawaczeck, Laura
    Bedke, Jens
    Rausch, Steffen
    Stenzl, Arnulf
    FUTURE ONCOLOGY, 2020, 16 (21) : 1511 - 1523
12345